The Diagnosis and Treatment of Hypoactive Sexual Desire Disorder

The Diagnosis and Treatment of Hypoactive Sexual Desire Disorder

The Diagnosis and Treatment of Hypoactive Sexual Desire Disorder
ECHO™ A CME Self-Study Activity: The Diagnosis and Treatment of Hypoactive Sexual Desire Disorder

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Hypoactive sexual desire disorder, or HSDD, is the most common female sexual dysfunction with about 10% of premenopausal women in the US believed to have this condition. HSDD is consistently under diagnosed, and under managed due to the lack of adequate physician-patient communication on this topic.

    In this article, Dr. Mache Seibel will discuss the symptoms of HSDD, and its impact on a patient’s quality of life along with the components for a comprehensive sexual history. Also discussed will be the tools for screening and diagnosing HSDD, as well as therapeutic modalities available and processes of the FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) Program.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Mache Seibel, MD
    Faculty, Department of Ob/Gyn
    Beth Israel Hospital
    Harvard Medical School
    Boston, MA

    Dr. Seibel has nothing to disclose.


    • Sean T. Barrett has nothing to disclose.
    • Carole Drexel, PhD, CHCP has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Ashley Rosenthal has nothing to disclose.
    • Robert Schneider, MSW has nothing to disclose.


  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the symptoms of hypoactive sexual desire disorder
    • Cite barriers in their clinical practice that inhibit the appropriate diagnosis and management of HSDD
    • Describe the components of a comprehensive sexual history
    • Identify the screening tools that allow for accurate diagnosis of HSDD
    • Explain causal factors for HSDD and common co-morbid conditions
    • Identify the therapeutic modalities available to manage HSDD including their benefits and potential side effects – also including the first agent approved for this indication (flibanserin)
    • Identify the processes of the FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) Program that will allow healthcare providers/pharmacies to prescribe/dispense flibanserin
  • Target Audience

    This activity is designed to meet the educational needs of the obstetrician and gynecologist, family physician, internal medicine physician, physician assistant, nurse practitioner, and certified nurse midwife.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

  • Commercial Support

    This activity is supported by an independent educational grant from Valeant Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign-up for the Omnia Education newsletters.
Comprehensive women’s health CME.

Better education for a better you.

* Required

Join Omnia Education's community of women's health professionals.
Registration is free and easy.

Register Now